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processes and decisions. The health economics and health policy
literature was reviewed for commentaries and case studies of par-
ticular decisions. Where decisions had been made by different
bodies on the same technology those were reviewed for consis-
tency. Parallels were drawn with methods of regulating market
access in other European countries. RESULTS: NICE procedures
were the most thorough but could not be applied early or to all
technologies because of their resource- intensive nature. Method-
ological expectations for company submissions were similar
between organisations, but the degree of independent review
varied with the annual number of technologies assessed. In 
most cases, NICE and SMC decisions on the same drug were
consistent. SMC most resembled equivalent systems in other
European countries by evaluating drugs at launch. AWMSG was
most concerned with budget impact. CONCLUSIONS: Most dif-
ferences between the organisations could be explained by their
differing objectives, scope of activities and timing of their inter-
vention. The SMC was more concerned with timely and com-
prehensive coverage of all drugs, reﬂecting its closer links to
NHS. NICE was only beginning to address implementation.
Properly co-coordinated, the sequence of evaluations could
follow a logical development of evidence quality over time, with
minimal redundant work on company submissions. Without
such co-ordination a waste of valuable time and resources is
likely.
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OBJECTIVE: The Medicare Prescription Drug, Improvement
and Modernization Act (MMA) of 2003 directed the Medicare
Payment Advisory Commission (MedPAC) to conduct a study of
hospital pharmacy handling costs. The June 2005 MedPAC
report recommended payment for handling costs of Part B spec-
iﬁed outpatient drugs based on submitted charges, reduced to
costs. This study explores policy implications of MedPAC rec-
ommendations concerning potential OPPS pharmacy handling
cost payment methodology. METHODS: Various methods of
recording charges for pharmacy services were collected from a
hospital survey of systems (n = 399) and categorized. Past CMS
and MedPAC discussions of pharmacy costs and charges were
identiﬁed and accumulated in an indexed database. Findings
from the hospital sources and the governmental sources were
compared and underlying assumptions examined with a view
toward predicting 2006 CMS approaches to determining hospi-
tal pharmacy handling cost payment. RESULTS: The hospital
survey revealed signiﬁcant variation in whether hospital phar-
macy department drug charges recognize overhead such as han-
dling costs. Forty-three percent of survey respondents did include
such a charge. Types of charges reported were for dispensing
(35%), compounding (25%), a combination of dispensing and
compounding (23%) and all other (17%). When entries in the
indexed database of CMS and MedPAC discussions of pharmacy
costs and charges were compared to the hospital responses about
actual departmental cost and charge methods currently in use,
analyses revealed a signiﬁcant differential between methods
reported by hospital respondents (including charge compression)
and methods discussed in published CMS and MedPAC sources.
CONCLUSIONS: Future payment rates for hospital pharmacy
handling costs will likely be derived from hospital submitted
charges, per the MedPAC recommendation. If the payment
methodology does not take existing variations of recording phar-
macy costs and charges into account, the resulting method will
be signiﬁcantly ﬂawed and hospital providers may ﬁnd they are
underpaid for pharmacy handling costs in 2006.
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OBJECTIVES: The Spanish Agency of Medicines and Health
care Products (SAMHP) makes regulatory decisions concerning
pharmacovigilance. Here, we analyse the impact of actions
related to safety adopted by the SAMHP on drug consumption
ﬁnanced by the Spanish National Health System (NHS), over the
period 1990–2004. METHODS: A retrospective analysis of the
consumption was made, selecting drugs which were eventually
withdrawn from the market. Consumption data was provided
by the Ministry of Health and Consume (MHC) database and
expressed as number of prescriptions. Drugs selected were 
classiﬁed according to type of Adverse Drug Reaction (ADR),
Anatomic Therapeutic-Chemical Classiﬁcation (ATC) and degree
of therapeutic innovation at the moment of authorisation,
according to the MHC. RESULTS: Fourteen drugs were selected
for the purpose of this study, and none of these were categorised
as “an exceptional therapeutic novelty”. The most common
ADRs concerned severe liver (7/14) or heart (5/7) toxicity. At
least 8 of the 14 drugs were associated with one safety action
before being withdrawn. This was either a product labeling 
modiﬁcation (astemizole, droxicam, nimesulide, nefazodone,
cerivastatine, trovaﬂoxacine, and rofecoxib) or classiﬁcation as
hospitalary diagnostic (cisapride). Rofecoxib was the only one
with two actions. A high level of consumption and in a very short
time from authorisation until the ﬁrst safety action (between one
to three years) was found in nimesulide, cerivastatine and rofe-
coxib. In the rest of the drugs, the only action was the with-
drawn. This happened after one year post-authorisation
(tolcapone, sertindol, and grepaﬂoxacine) or in the case of ebro-
tidine, two years. CONCLUSIONS: The drugs withdrawn after
one or two years from their authorisation would seem reason-
able not have been ﬁnanced by NHS. In all drugs, the ﬁrst safety
action resulted in a signiﬁcant decrease in consumption. In some
of these cases, manufacturers requested to SAMHP drug to be
withdrawn.
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OBJECTIVES: To determine the effects of implementing essen-
tial medicines list on rational use of medicines and medicine cost
savings in the public sector of West Bank, Palestine. METHODS:
The effect of EML on medicine expenditure was divided into two
separate components: the effect of EML on quantities used, and
the effect on medicine prices. The quantities of 76 medicine
groups were used as the dependent variable with real GDP per
capita, EML dummy, hospital dummy, time, and percent of
insured population, as independent variables. Another set of
regressions were deﬁned with real medicine price per deﬁned
daily dose as dependent variable and real GDP per capita, EML,
and percent insured as independent variables. A sample of pre-
scriptions was also analyzed to measure the indices of rational
medicine use. The indicators of rational use of medicines were
assumed to be a function of EML, and 16 health center dummy
